About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA).
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 7738 record(s)
Req # A-2019-000842
Adverse Reaction Report (AER). Report numbers: E2B_01929194, E2B_01926477, E2B_01917015, E2B_02080279, E2B_02097661, E2B_02106036, E2B_01894417, E2B_01894417, E2B_02108840 and E2B_01880486.Organization: Health Canada
March 2020
Req # A-2019-000893
Adverse Reaction Report (AER). Report numbers: E2B_02460032, E2B_02473329, E2B_02476812, E2B_02476819, E2B_02476989.Organization: Health Canada
March 2020
Req # A-2019-001035
Adverse Reaction Report (AER). Report number: E2B_02532680.Organization: Health Canada
March 2020
Req # A-2019-001121
Adverse Reaction Report (AER). Report number: E2B_02319741.Organization: Health Canada
March 2020
Req # A-2019-001152
Briefing note in the Ministerial Executive Correspondence System (MECS) for the following file: 18-107225-330, Publication of the Final Screening Assessment for Aspergillus awamori and Aspergillus brasiliensis under the Chemicals Management Plan.Organization: Health Canada
March 2020
Req # A-2019-001154
Adverse Reaction Report (AER). Report numbers: E2B_01534925, E2B_01661193, E2B_00052927, E2B_01913970, E2B_02161866 000502861, E2B_00953236, E2B_00780720, E2B_01310941, E2B_01310936.Organization: Health Canada
March 2020
Req # A-2019-001161
Adverse Reaction Report (AER). Report number: E2B_02541309.Organization: Health Canada
March 2020
Req # A-2019-001168
Adverse Reaction Report (AER). Report numbers: E2B_02105324, E2B_02105424, E2B_02091312, E2B_02120369, E2B_02066936 E2B_02127350, E2B_02043772, E2B_02073410, E2B_02150148, E2B_02147905, E2B_02145596, E2B_01995214, E2B_02020446, E2B_02020699 E2B_01969836, E2B_01991676.Organization: Health Canada
March 2020
Req # A-2019-001202
Adverse Reaction Report (AER). Report number: E2B_02324483.Organization: Health Canada
March 2020
Req # A-2019-001203
Adverse Reaction Report (AER). Report numbers: E2B_01608080, E2B_01659266, E2B_00058752, E2B_00039508, E2B_01894339, E2B_02534470, E2B_01524801, E2B_01874540, E2B_02237129.Organization: Health Canada
March 2020